Connacht Asset Management’s AstraZeneca AZN Stock Holding History

Connacht Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,739	Closed	-$380K	–	99
2023 Q1	$380K	Sell	2,739 -4,583	-63%	-$617K	0.16%	94
2022 Q4	$993K	Sell	7,322 -1,242	-15%	-$156K	0.45%	46
2022 Q3	$939K	Sell	8,564 -2,894	-25%	-$367K	0.67%	42
2022 Q2	$1.51M	Buy	+11,458	New	+$1.5M	0.64%	37

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Connacht Asset Management's AZN Position: Q2 2023 in Review

Connacht Asset Management sold out of AstraZeneca (AZN) in Q2 2023, closing a stake of 2,739 shares — an estimated $380K sold.

Connacht Asset Management first reported a position in AZN in Q2 2022 and held it in 4 quarters. The position peaked at $1.51M in Q2 2022. 1,092 funds tracked by Wall St. Rank hold AZN as of Q2 2023.

Connacht Asset Management reported no remaining AstraZeneca position as of Q2 2023 after selling out during the quarter.
Connacht Asset Management sold 2,739 AstraZeneca shares in Q2 2023, an estimated $380K.
Connacht Asset Management first reported a position in AstraZeneca in Q2 2022 and held it in 4 quarters.
Connacht Asset Management's AstraZeneca position peaked at $1.51M in Q2 2022.
1,092 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2023.

Based on Connacht Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.